Literature DB >> 6319181

New potent inhibitors of angiotensin converting enzyme.

M R Attwood, R J Francis, C H Hassall, A Kröhn, G Lawton, I L Natoff, J S Nixon, S Redshaw, W A Thomas.   

Abstract

Using an earlier model of the favoured orientation of binding functions of angiotensin converting enzyme (ACE) inhibitors, it has been possible to postulate a new, 7,6-bicyclic system, based on hexahydropyridazine, which might be expected to have high potency. Some members of this system which have been synthesised have been shown to be very active ACE inhibitors, in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319181     DOI: 10.1016/0014-5793(84)80169-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

Review 1.  Prodrugs.

Authors:  D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

2.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Sequential allylic C-H amination/vinylic C-H arylation: a strategy for unnatural amino acid synthesis from α-olefins.

Authors:  Chao Jiang; Dustin J Covell; Antonia F Stepan; Mark S Plummer; M Christina White
Journal:  Org Lett       Date:  2012-02-24       Impact factor: 6.005

Review 4.  Preclinical studies on angiotensin converting enzyme inhibitors.

Authors:  I L Natoff
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

5.  Vascular protection with cilazapril.

Authors:  J P Clozel; J S Powell; H Kuhn; R K Müller; F Hefti; H R Baumgartner
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 6.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

7.  Chemical design of cilazapril.

Authors:  M R Attwood
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function.

Authors:  H Shionoiri; E Gotoh; K Sugimoto; I Takasaki; K Minamisawa; M Ishii
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 9.  A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.

Authors:  J F Waterfall
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

10.  Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats.

Authors:  J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.